11:00
Welcome & Opening Address by Conference Chairman
Dr Jean-Paul RENAUD
URANIA THERAPEUTICS, Ostwald, France
11:05
Keynote Lecture 1 - The Combined Use of Structural Biology and Biophysics at Astex for FBDD
Dr Marc O'REILLY
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom
Marc O'Reilly studied physics at Imperial College (London) and completed a D.Phil in structural biology in Professor Dame Louise Johnson’s group at the Laboratory of Molecular Biophysics (Oxford) prior to taking up a post-doctoral research position at the MRC Laboratory of Molecular Biology (Cambridge, UK). Marc joined Astex Pharmaceuticals in 2000 and is currently VP, Molecular Sciences.
11:50
NovAliX at Present
Mr Stephan JENN
NOVALIX, Illkirch, France
Dr Denis ZEYER
NOVALIX, Illkirch, France
12:00
Keynote Lecture 2 - Discovery of Small Molecule mRNA Drugs and their Mechanisms of Action using Phenotypic Screening with AI-driven MOA Elucidation
Dr Iris ALROY
ANIMA BIOTECH INC., Ramat Gan, Israel
Iris Alroy, Ph.D. has 25 years of experience in drug discovery, preclinical and early clinical development. Dr. Alroy has served as CSO of Anima since 2015, supervising drug discovery and pipeline development in the emerging field of mRNA translation regulation. Prior to Anima, she acted as VP of Discovery at Proteologics and Pharmos Corp. and CEO of several startup biotech companies, including Fusimab, Ltd. and ProMining Therapeutics Ltd.
12:45
Closing Remarks
Dr Jean-Paul RENAUD
URANIA THERAPEUTICS, Ostwald, France